Unknown

Dataset Information

0

Comparison of MAPIE versus MAP in patients with a poor response to preoperative chemotherapy for newly diagnosed high-grade osteosarcoma (EURAMOS-1): an open-label, international, randomised controlled trial.


ABSTRACT:

SUBMITTER: Marina NM 

PROVIDER: S-EPMC5052459 | biostudies-literature | 2016 Oct

REPOSITORIES: biostudies-literature

altmetric image

Publications

Comparison of MAPIE versus MAP in patients with a poor response to preoperative chemotherapy for newly diagnosed high-grade osteosarcoma (EURAMOS-1): an open-label, international, randomised controlled trial.

Marina Neyssa M NM   Smeland Sigbjørn S   Bielack Stefan S SS   Bernstein Mark M   Jovic Gordana G   Krailo Mark D MD   Hook Jane M JM   Arndt Carola C   van den Berg Henk H   Brennan Bernadette B   Brichard Bénédicte B   Brown Ken L B KLB   Butterfass-Bahloul Trude T   Calaminus Gabriele G   Daldrup-Link Heike E HE   Eriksson Mikael M   Gebhardt Mark C MC   Gelderblom Hans H   Gerss Joachim J   Goldsby Robert R   Goorin Allen A   Gorlick Richard R   Grier Holcombe E HE   Hale Juliet P JP   Hall Kirsten Sundby KS   Hardes Jendrik J   Hawkins Douglas S DS   Helmke Knut K   Hogendoorn Pancras C W PCW   Isakoff Michael S MS   Janeway Katherine A KA   Jürgens Heribert H   Kager Leo L   Kühne Thomas T   Lau Ching C CC   Leavey Patrick J PJ   Lessnick Stephen L SL   Mascarenhas Leo L   Meyers Paul A PA   Mottl Hubert H   Nathrath Michaela M   Papai Zsuzsanna Z   Randall R Lor RL   Reichardt Peter P   Renard Marleen M   Safwat Akmal Ahmed AA   Schwartz Cindy L CL   Stevens Michael C G MCG   Strauss Sandra J SJ   Teot Lisa L   Werner Mathias M   Sydes Matthew R MR   Whelan Jeremy S JS  

The Lancet. Oncology 20160825 10


<h4>Background</h4>We designed the EURAMOS-1 trial to investigate whether intensified postoperative chemotherapy for patients whose tumour showed a poor response to preoperative chemotherapy (≥10% viable tumour) improved event-free survival in patients with high-grade osteosarcoma.<h4>Methods</h4>EURAMOS-1 was an open-label, international, phase 3 randomised, controlled trial. Consenting patients with newly diagnosed, resectable, high-grade osteosarcoma aged 40 years or younger were eligible for  ...[more]

Similar Datasets

| S-EPMC7893483 | biostudies-literature
| S-EPMC4486345 | biostudies-literature
| S-EPMC6240354 | biostudies-literature
| S-EPMC4304379 | biostudies-literature
2024-07-17 | GSE267013 | GEO
| S-EPMC11742561 | biostudies-literature
| S-EPMC3772178 | biostudies-other
| S-EPMC9096723 | biostudies-literature
| S-EPMC10402363 | biostudies-literature
| S-EPMC3663793 | biostudies-literature